Sensei Biotherapeutics (NASDAQ:SNSE) Stock Rating Reaffirmed by HC Wainwright

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.20) EPS, FY2025 earnings at ($0.92) EPS and FY2026 earnings at ($1.04) EPS.

Several other equities research analysts also recently commented on the stock. Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Sensei Biotherapeutics in a research note on Friday, May 24th. Citigroup reiterated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research note on Monday, June 3rd.

Sensei Biotherapeutics Price Performance

SNSE stock traded down $0.02 during trading on Wednesday, hitting $0.62. 791 shares of the company’s stock traded hands, compared to its average volume of 131,314. Sensei Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.07 and a current ratio of 12.07. The business has a fifty day simple moving average of $0.66 and a two-hundred day simple moving average of $0.90.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. As a group, sell-side analysts predict that Sensei Biotherapeutics will post -1.09 EPS for the current fiscal year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.